Overview

Proof-of-concept Study of Forward Pharma (FP)187 in Patients With Mild/Moderate Psoriatic Arthritis

Status:
Withdrawn
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate, whether FP187 is effective in the treatment of mild to moderate psoriatic arthritis.
Phase:
Phase 2
Details
Lead Sponsor:
Skane University Hospital
Treatments:
Dimethyl Fumarate